FindTrial
Sign In

Avelumab (MSB0010718C)

DRUG4 trials

Sponsors

Pfizer

Conditions

Carcinoma, HepatocellularNon-Small Cell Lung CancerRenal Cell CancerUrothelial Cancer

Phase 1

A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)
CompletedNCT02493751
PfizerRenal Cell Cancer
Start: 2015-10-26End: 2021-03-04Updated: 2022-02-18
A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
CompletedNCT03289533
PfizerCarcinoma, Hepatocellular
Start: 2017-09-08End: 2019-10-25Updated: 2020-09-04

Phase 2

A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
TerminatedNCT03472560
PfizerNon-Small Cell Lung Cancer, Urothelial Cancer
Start: 2018-05-02End: 2023-02-09Updated: 2024-04-09

Phase 3

A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
CompletedNCT02684006
PfizerRenal Cell Cancer
Start: 2016-03-23End: 2024-06-26Updated: 2025-07-30

Related Papers

Cardiac Biomarkers in Patients With Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors.
2026-03-30
Real-world effectiveness and safety of avelumab + axitinib combination in first-line treatment of UK patients with advanced renal cell carcinoma
ESMO Real World Data and Digital Oncology2025-11-06
8The actionable microbial gut checkpoint MAdCAM-1 in patients with advanced renal cell carcinoma
The Oncologist2025-10-01
Gut-associated checkpoint as a prognostic biomarker in metastatic renal cell carcinoma (mRCC): Results from a randomized first-line clinical trial.
Journal of Clinical Oncology2025-05-282 citations
Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.
2024-12-1822 citations
Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response
Cell Reports Medicine2024-11-2516 citations
Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.
Journal of Clinical Oncology2024-06-0126 citations
Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial
BMJ Oncology2024-06-018 citations
189 Systematic evaluation of transcriptomic molecular features in advanced renal clear cell carcinoma treated with immunotherapy
Regular and Young Investigator Award Abstracts2023-10-31
Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial.
2023-10-1615 citations
Plain Language Summary Looking at How Long Side Effects Last After Treatment with Axitinib is Stopped in People with Advanced Renal Cell Carcinoma
Future Oncology2023-08-012 citations
A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer.
2023-05-028 citations
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
ESMO Open2023-04-2551 citations
Extensive CArdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study
Pharmaceuticals2023-04-208 citations
C-reactive protein (CRP) as a predictive marker for outcomes with avelumab + axitinib (A + Ax) in patients with poor-risk advanced renal cell carcinoma (aRCC): Exploratory analysis from JAVELIN Renal 101.
Journal of Clinical Oncology2023-02-20
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial
The Oncologist2022-12-2813 citations
Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience.
Journal of Clinical Oncology2022-06-013 citations
Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
Clinical Cancer Research2021-11-1732 citations
The use of a new combination of avelumab + axitinib in patients with metastatic kidney cancer in the first line of treatment
Meditsinskiy sovet = Medical Council2021-06-12
Efficacy of avelumab + axitinib (A + Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.
Journal of Clinical Oncology2021-05-2018 citations

27 more papers not shown